secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cardiff Oncology, Inc. (CRDF)
CIK:        0001213037
Form:       8-K
Filed at:   2025-06-17T23:59:59+00:00
Accession:  0000950170-25-087369
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cardiff Oncology appoints Dr. Roger Sidhu as CMO; to share CRDF-004 data on July 29
--------------------------------------------------------------------------------

- Dr. Fairooz Kabbinavar stepped down as CMO effective June 13, 2025; will remain as advisor.
- Dr. Roger Sidhu appointed CMO; previously at Amgen, Treadwell Therapeutics, Roivant Sciences.
- Sidhu receives $515K base salary, 45% target bonus, and option for 600K shares at $3.86 vesting over 4 years.
- Company to report additional clinical data from Phase 2 CRDF-004 trial in RAS-mutated mCRC on July 29, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1213037/000095017025087369/0000950170-25-087369-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1213037/000095017025087369/crdf-20250613.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-087369

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer